ZYUS Life Sciences Corporation Secures Unsecured Loan
ZYUS Life Sciences Corporation (TSX-V: ZYUS), a promising life sciences company in cannabinoid-based pharmaceuticals, has recently announced an exciting financial development. An independent director of the company, referred to as the Lender, has agreed to provide the Company with a significant unsecured loan of CAD$2,000,000. This loan underscores the confidence that insiders have in the potential and future of ZYUS.
Key Loan Details and Terms
The loan is set to close on or around a specified date, pending the necessary notification to the TSX Venture Exchange. This loan will carry a 12% annual interest rate and is structured to be payable at maturity. Furthermore, ZYUS retains the flexibility to prepay the loan at any point without incurring penalties. The maturity date is noted as either May 5, 2025, or aligned with future treasury offerings if gross proceeds exceed a specified amount.
Related Party Transaction Implications
This financial agreement is noted as a related party transaction, given that the Lender holds a director position within the company. Accordingly, to comply with regulatory frameworks, the Lender abstained from participating in the decision-making process regarding the loan's approval. This protocol ensures transparency and adherence to the guidelines outlined in Multilateral Instrument 61-101.
Management's Perspective on the Loan
Brent Zettl, the President and CEO of ZYUS, expressed optimism about the loan arrangement, emphasizing the company's commitment to advancing innovative solutions for pain management. He highlighted that this financial backing reflects a strong insider commitment to ZYUS' mission, particularly in clinical trial activities aimed at developing non-opioid therapies.
Utilization of Funds
The proceeds from this loan are earmarked for general working capital purposes. This funding is an essential component in supporting ZYUS' ongoing initiatives and future advancements in the cannabinoid pharmaceutical landscape. The company is fully focused on transforming patients' lives through effective pain management solutions.
About ZYUS Life Sciences Corporation
Established to revolutionize pain management, ZYUS is dedicated to developing and commercializing groundbreaking cannabinoid-based pharmaceutical candidates. By prioritizing rigorous research and clinical trials, ZYUS aims to protect its innovative therapies with robust intellectual property rights, thereby enhancing shareholder value. Furthermore, the company is committed to obtaining necessary regulatory approvals for its non-opioid-based solutions, which represents a profound step towards offering alternatives in pain management.
Frequently Asked Questions
What is the main purpose of the CAD$2,000,000 loan for ZYUS?
The loan will primarily be used for general working capital purposes and to support ZYUS’ ongoing clinical research activities.
Who is providing the loan to ZYUS Life Sciences Corporation?
The loan is being provided by an independent director of the company, referred to as the Lender.
What is the interest rate of the unsecured loan?
The loan will bear an annual interest rate of 12%.
When is the loan expected to mature?
The maturity date of the loan is established as either May 5, 2025, or upon the completion of certain treasury offerings.
What type of therapies is ZYUS focused on developing?
ZYUS is primarily focused on developing cannabinoid-based pharmaceutical therapies aimed at providing non-opioid alternatives for pain management.